Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ketogenic diet · 1 trial · 1 indication
Early treatment discontinuation, treatment compliance, 7-point Licker hunger scale, fasting lipid levels and fasting serum glucose and insulin levels
| Arm | Type | Description |
|---|---|---|
| ketogenic diet | EXPERIMENTAL | Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. |
| Name | Type | Description |
|---|---|---|
| ketogenic diet | OTHER | Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard. |
Inclusion Criteria: 1. Age 18-65 2. Ability and willingness to signed informed consent form. 3. Astrocytoma grade 4 (glioblastoma multiforme, GBM, histologically confirmed, WHO criteria) 4. Documented recurrence or progression after surgical resection/debulking, radiation and temozolamide chemother...
Ketogenic Diet, Standardized Diet is an investigational dietary intervention being studied as an adjunctive treatment for Glioblastoma Multiforme, a type of brain cancer. It is being evaluated in clinical trials to assess its potential role alongside standard therapies such as radiation and chemotherapy for this condition.
Ketogenic Diet, Standardized Diet is being developed by Atlantic International Corp., a company traded under the ticker symbol ATLN. The company is conducting clinical research to evaluate this dietary approach in the context of glioblastoma multiforme treatment.
Ketogenic Diet, Standardized Diet is currently in Phase 2 clinical development for glioblastoma multiforme. It remains an investigational dietary intervention and has not been approved by regulatory authorities. Its clinical program includes completed trials that have evaluated its safety and feasibility.
Ketogenic Diet, Standardized Diet has been studied in two completed clinical trials. NCT01865162 was a Phase 1 pilot study in refractory or end-stage glioblastoma multiforme with 6 participants. NCT02302235 was a Phase 2 pilot study testing the diet as an adjunct to radiation and chemotherapy in glioblastoma multiforme, enrolling 42 participants.
Ketogenic Diet, Standardized Diet refers to a specific standardized formulation of a ketogenic diet being investigated as a therapeutic intervention. It is distinct from general dietary recommendations, as it is being developed and studied in a controlled clinical setting for its potential effects on glioblastoma multiforme.